Upgrade to SI Premium - Free Trial

Stifel on Viridian (VRDN): 'We view positive REVEAL-2 chronic TED data in 2Q26 as important'

April 6, 2026 9:46 AM
Stifel analyst Alex Thompson reiterated a Buy rating and $48.00 price target on Viridian Therapeutic (NASDAQ: VRDN).The analyst comments "AMGN ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles